title: Hospital guidelines for use of low-molecular-weight heparins.
abstract: OBJECTIVE
  To describe the development of guidelines for initial use of low-molecular-weight heparins (LMWHs) and other anticoagulants in acute-care hospitals that are part of a national group purchasing organization (GPO).
  
  
  METHODS
  A systematic literature search (1970-December 2001) was conducted to identify evidence on the efficacy of various anticoagulants for initial therapy in deep-vein thrombosis and pulmonary embolism, and in treatment of acute coronary syndrome. A group consensus method was then used to develop guidelines. Guidelines were reviewed and revised by an internal expert panel as well as an external expert panel. Final guidelines were disseminated to GPO members and assistance was provided with implementation at the local level.
  
  
  RESULTS
  The final set of guidelines is described. The guidelines are organized based on recommended therapeutic options for each indication. For each option, consensus opinion is provided on the level of evidence that exists in the literature, comparisons of cost and convenience, and additional dosing information. The guidelines were disseminated along with supporting material to interested GPO member hospitals, and teleconferences were held to facilitate implementation at the local level. The guidelines were initially implemented at 18 hospitals across the country.
  
  
  CONCLUSIONS
  The process by which these guidelines were developed, plus the final set of guidelines, may be useful to hospitals and healthcare systems contemplating or engaged in a similar effort with this class of drugs.
authors.affiliation: Antithrombosis Services, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: Edith A
authors.initials: EA
authors.lastname: Nutescu
authors.forename: Richard K
authors.initials: RK
authors.lastname: Lewis
authors.forename: Jamie M
authors.initials: JM
authors.lastname: Finley
authors.forename: Glen T
authors.initials: GT
authors.lastname: Schumock
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy; D017754:Group Purchasing; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy; D020246:Venous Thrombosis / Q000188:drug therapy
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight